Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
- PMID: 30167705
- PMCID: PMC7391072
- DOI: 10.1001/jama.2018.11406
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Abstract
Importance: Alcohol consumption is associated with 88 000 US deaths annually. Although routine screening for heavy alcohol use can identify patients with alcohol use disorder (AUD) and has been recommended, only 1 in 6 US adults report ever having been asked by a health professional about their drinking behavior. Alcohol use disorder, a problematic pattern of alcohol use accompanied by clinically significant impairment or distress, is present in up to 14% of US adults during a 1-year period, although only about 8% of affected individuals are treated in an alcohol treatment facility.
Observations: Four medications are approved by the US Food and Drug Administration to treat AUD: disulfiram, naltrexone (oral and long-acting injectable formulations), and acamprosate. However, patients with AUD most commonly receive counseling. Medications are prescribed to less than 9% of patients who are likely to benefit from them, given evidence that they exert clinically meaningful effects and their inclusion in clinical practice guidelines as first-line treatments for moderate to severe AUD. Naltrexone, which can be given once daily, reduces the likelihood of a return to any drinking by 5% and binge-drinking risk by 10%. Randomized clinical trials also show that some medications approved for other indications, including seizure disorder (eg, topiramate), are efficacious in treating AUD. Currently, there is not sufficient evidence to support the use of pharmacogenetics to personalize AUD treatments.
Conclusions and relevance: Alcohol consumption is associated with a high rate of morbidity and mortality, and heavy alcohol use is the major risk factor for AUD. Simple, valid screening methods can be used to identify patients with heavy alcohol use, who can then be evaluated for the presence of an AUD. Patients receiving a diagnosis of the disorder should be given brief counseling and prescribed a first-line medication (eg, naltrexone) or referred for a more intensive psychosocial intervention.
Comment in
-
Medications for Alcohol Use Disorder and Predicting Severe Withdrawal.JAMA. 2018 Aug 28;320(8):766-768. doi: 10.1001/jama.2018.10061. JAMA. 2018. PMID: 30167678 No abstract available.
Similar articles
-
Overview of Alcohol Use Disorder.Am J Psychiatry. 2023 Aug 1;180(8):565-572. doi: 10.1176/appi.ajp.20230488. Am J Psychiatry. 2023. PMID: 37525595 Review.
-
Pharmacologic interventions for alcohol use disorder.JAAPA. 2025 Jun 1;38(6):e2-e6. doi: 10.1097/01.JAA.0000000000000106. Epub 2025 May 27. JAAPA. 2025. PMID: 40421949 Review.
-
Pharmacological treatment of alcohol dependence: a review of the evidence.JAMA. 1999 Apr 14;281(14):1318-25. doi: 10.1001/jama.281.14.1318. JAMA. 1999. PMID: 10208148
-
Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.Alcohol Alcohol. 2007 Jul-Aug;42(4):333-9. doi: 10.1093/alcalc/agm038. Epub 2007 May 21. Alcohol Alcohol. 2007. PMID: 17517820 Clinical Trial.
-
Introduction: Approved treatments for alcohol use disorder by regulatory agencies.Int Rev Neurobiol. 2024;178:1-22. doi: 10.1016/bs.irn.2024.07.001. Epub 2024 Oct 18. Int Rev Neurobiol. 2024. PMID: 39523052 Review.
Cited by
-
Novel intervention for alcohol-associated liver disease.World J Gastroenterol. 2024 Oct 21;30(39):4308-4312. doi: 10.3748/wjg.v30.i39.4308. World J Gastroenterol. 2024. PMID: 39492829 Free PMC article.
-
Cyclic Nucleotide Phosphodiesterases in Alcohol Use Disorders: Involving Gut Microbiota.Int J Neuropsychopharmacol. 2023 Jan 19;26(1):70-79. doi: 10.1093/ijnp/pyac060. Int J Neuropsychopharmacol. 2023. PMID: 36087271 Free PMC article.
-
Impulsive trait mediates the relationship between white matter integrity of prefrontal-striatal circuits and the severity of dependence in alcoholism.Front Psychiatry. 2022 Sep 7;13:985948. doi: 10.3389/fpsyt.2022.985948. eCollection 2022. Front Psychiatry. 2022. PMID: 36159935 Free PMC article.
-
A matched-control analysis on the effects of alcohol use disorder following primary reverse shoulder arthroplasty.J Orthop. 2021 Feb 24;24:186-189. doi: 10.1016/j.jor.2021.02.033. eCollection 2021 Mar-Apr. J Orthop. 2021. PMID: 33737792 Free PMC article.
-
Sexually dimorphic role of circadian clock genes in alcohol drinking behavior.Psychopharmacology (Berl). 2023 Mar;240(3):431-440. doi: 10.1007/s00213-022-06247-w. Epub 2022 Oct 3. Psychopharmacology (Berl). 2023. PMID: 36184679 Review.
References
-
- Center for Behavioral Health Statistics and Quality. 2016 National Survey on Drug Use and Health: Detailed Tables Substance Abuse and Mental Health Services Administration, Rockville, MD, 2017. Retrieved from: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH.... Accessed June 16, 2018.
-
- Centers for Disease Control and Prevention (CDC). 2013. Alcohol and public health: Alcohol-related disease impact (ARDI). Average for United States 2006–2010 alcohol-attributable deaths due to excessive alcohol use. Available at: https://nccd.cdc.gov/DPH_ARDI/Default/Report.aspx?T=AAM&P=f6d7eda7-036e-.... Accessed April 19, 2018.
-
- Centers for Disease Control and Prevention. Excessive drinking is draining the U.S. economy. Centers for Disease Control and Prevention; 2016. Available at: https://www.cdc.gov/features/costsofdrinking/index.html. Accessed April 19, 2018.
-
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing, 2013.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical